Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18125160 | 1.00 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL16326391 | 1.00 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL1659096 | 0.92 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL8897150 | 0.90 | LMNA (0.42) | ALDH1A1TSHRLMNAHSD17B10MEN1 | |
| SCHEMBL6330793 | 0.90 | LMNA (0.42) | ALDH1A1TSHRLMNAHSD17B10MEN1 | |
| SCHEMBL1660093 | 0.90 | LMNA (0.42) | ALDH1A1TSHRLMNAHSD17B10MEN1 | |
| SCHEMBL6322458 | 0.90 | LMNA (0.42) | ALDH1A1TSHRLMNAHSD17B10MEN1 | |
| SCHEMBL1658351 | 0.83 | — | — | |
| SCHEMBL6060705 | 0.83 | ACACB (0.37) | TDP1 | |
| SCHEMBL7248706 | 0.81 | TDP1 (0.40) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117440992-A | Use of a composition in optical measurement applications | F2MB-工程公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017048727-A1 | MODULATORS OF TOLL-LIKE RECPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20100317872-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7799821-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7674786-B2 | Therapeutic β-lactams | ALLERGAN, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
| US-20090186866-A1 | THERAPEUTIC BETA-LACTAMS | ALLERGAN, INC. | 2009-07-23 | — | — | US | disclosed |
| US-20080113943-A1 | Therapeutic Beta-Lactams | ALLERGAN, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-7186782-B2 | Hydrogenation catalyst composition and process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2007-03-06 | — | — | US | disclosed |
| US-20060041079-A1 | Hydrogenation catalyst composition and process for hydrogenation of conjugated diene polymer | TSRC CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-6881797-B2 | Process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2005-04-19 | — | — | US | disclosed |
| US-20040082727-A1 | Process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (CN) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | ALDH1A1 3811/4885SMN1; SMN2 4646/4885TSHR 1106/4885 |
| US-20090186866-A1 | THERAPEUTIC BETA-LACTAMS | NRDC, DDO, DAO | ALDH1A1 1258/4885SMN1; SMN2 1965/4885TSHR 3545/4885 |
| US-20080113943-A1 | Therapeutic Beta-Lactams | NRDC, DDO, DAO | ALDH1A1 1258/4885SMN1; SMN2 1965/4885TSHR 3545/4885 |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | ALDH1A1 3811/4885SMN1; SMN2 4646/4885TSHR 1106/4885 |
| US-20100317872-A1 | THERAPEUTIC COMPOUNDS | PTGER2, PTGES2, PTGER1 | ALDH1A1 2292/4885SMN1; SMN2 4423/4885TSHR 1027/4885 |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | ALDH1A1 3939/4885SMN1; SMN2 4563/4885TSHR 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.